Diarylcoumarins Inhibit Mycolic Acid Biosynthesis and Kill Mycobacterium Tuberculosis by Targeting Fadd32
Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32 Sarah A. Stanleya,b,c, Tomohiko Kawatea,b,c, Noriaki Iwasea,b,c, Motohisa Shimizua,b,c, Anne E. Clatworthya,b,c, Edward Kazyanskayaa, James C. Sacchettinid, Thomas R. Ioergere, Noman A. Siddiqif, Shoko Minamif, John A. Aquadroa, Sarah Schmidt Granta,b,c, Eric J. Rubinf, and Deborah T. Hunga,b,c,1 aInfectious Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA 02142; bDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114; cDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115; Departments of dBiochemistry and Biophysics and eComputer Science, Texas A&M University, College Station, TX 77843; and fDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115 Edited* by John J. Mekalanos, Harvard Medical School, Boston, MA, and approved May 30, 2013 (received for review February 1, 2013) Infection with the bacterial pathogen Mycobacterium tuberculosis not yet in clinical trials, include Benzothiazinones that target imposes an enormous burden on global public health. New anti- decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1) (2) and biotics are urgently needed to combat the global tuberculosis inhibitors of malate synthase, a glyoxylate shunt enzyme (10). In pandemic; however, the development of new small molecules is addition to their potential as drug candidates, these molecules hindered by a lack of validated drug targets. Here, we describe the are significant for having facilitated the identification of novel identification of a 4,6-diaryl-5,7-dimethyl coumarin series that kills targets for further efforts geared toward drug discovery.
[Show full text]